An interventional study of Sulforaphane and Placebo in Attention Deficit Disorder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Assistance Publique - Hôpitaux de Paris.
Among the 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 5 with no phase, and was the 6th registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →7 of the 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 5–12
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 8–16
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 7+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 7–18
By country, each count listing its studies:
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 72 across 1,439 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 77 across the 6 interventional studies, 80 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440992Assistance Publique - Hôpitaux de ParisIdentification of Early Biomarkers of Pre-school ADHD | 2027-03-01 |
| NCT06594536Assistance Publique - Hôpitaux de ParisStudy of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.
Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.
This is a randomised controlled trial with a double-blind control group. The aim is to test the efficacy of Sulforaphane versus placebo by comparing these two groups with a 1:1 ratio.
The primary objective is to evaluate the efficacy of sulforaphane treatment versus placebo on the total inattention and hyperactivity/impulsivity score measured by the ADHD-RS scale (parents) at 8 weeks in children aged 6 to 12 years suffering from ADHD.
The primary endpoint was the ADHD-RS parent inattention and hyperactivity/impulsivity score at 8 weeks.
Secondary objectives:
To assess the efficacy of sulforaphane treatment versus placebo at 2, 4 and 8 weeks in children aged 6-12 years with ADHD on:
To assess the effect of treatment with sulforaphane versus placebo on attention and inhibition at 4 and 8 weeks: using a specific neuropsychological assessment: CPT (Continuous Performance Test); symptoms of inattention and hyperactivity/impulsivity assessed by the teacher using the ADHD-RS self-questionnaire. Differences in behaviour may be observed depending on the context (school versus family). It is therefore important to have 2 sources of information for the ADHD-RS questionnaire: the parents and the teacher.
To assess the tolerability of treatment with sulforaphane from a clinical point of view (use of a PAERS (Paediatrician Adverse Events Rating Scale) and a biological point of view (blood count, AST, ALT, total and conjugated bilirubin, blood ionogram, urea, creatininemia, T4, TSH).
The subgroup of patients included in the Robert Debré Hospital will have a High Resolution Electroencephalogram (HR-EEG) in order to study the electroencephalographic markers of response to treatment with sulforaphane.
An interview to assess interest in and satisfaction with the treatment will be conducted with the parents (Robert Debré) and the child in the month following the end of the study as part of a qualitative study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prostaphane® is a dietary supplement based on SULFODYNE®, a broccoli seed extract standardised in free, stabilised sulforaphane. Patients will receive treatment for 8 weeks at the following dosage: * 1 capsule/day up to 50 kg, * 2 capsules/day from 50.1 to 90 kg; * 3 capsules/day above 90 kg, Each capsule contains 10mg of Sulforaphane.
Dietary Supplement: Sulforaphane
Patients will receive treatment for 8 weeks at the following dosage: * 1 capsule/day up to 50 kg, * 2 capsules/day from 50.1 to 90 kg; * 3 capsules/day above 90 kg, Each capsule contains placebo.
Other: Placebo
taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane
taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo
Inattention scores in ADHD-RS parents
Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents
Time frame: 8 weeks
Hyperactivity/impulsivity scores in ADHD-RS parents
Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents
Time frame: 8 weeks
Inattention scores in ADHD-RS parents
Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents
Time frame: 2, 4 and 12 weeks
Hyperactivity/impulsivity scores in ADHD-RS parents
Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents
Time frame: 2, 4 and 12 weeks
Social Responsiveness Scale (SRS) scores and sub-scores
Social Responsiveness Scale (SRS) scores and sub-scores
Time frame: 4, 8 and 12 weeks
Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score
Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score
Time frame: 2, 4, 8 and 12 weeks
Sustained attention and inhibition scores in the CPT (Continuous Performance Test)
Sustained attention and inhibition scores in the CPT (Continuous Performance Test)
Time frame: 4 and 8 weeks
CGI-S (Clinical Global Impression - Severity) score
CGI-S (Clinical Global Impression - Severity) score
Time frame: 4 and 8 weeks
CGI-I (Clinical Global Impression - Improvement) score
CGI-I (Clinical Global Impression - Improvement) score
Time frame: 4 and 8 weeks
ADHD-RS teacher inattention and hyperactivity/impulsivity scores
ADHD-RS teacher inattention and hyperactivity/impulsivity scores
Time frame: 4 and 8 weeks
tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale)
tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale)
Time frame: 4 and 8 weeks
tolerance of treatment: Blood sample: Blood count
tolerance of treatment: Blood sample: Blood count
Time frame: 8 weeks
tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase)
tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase)
Time frame: 8 weeks
tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase)
tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase)
Time frame: 8 weeks
tolerance of treatment: Blood sample: total bilirubin
tolerance of treatment: Blood sample: total bilirubin
Time frame: 8 weeks
tolerance of treatment: Blood sample: conjugated bilirubin
tolerance of treatment: Blood sample: conjugated bilirubin
Time frame: 8 weeks
tolerance of treatment: Blood sample: ionogram
tolerance of treatment: Blood sample: ionogram
Time frame: 8 weeks
tolerance of treatment: Blood sample: urea
tolerance of treatment: Blood sample: urea
Time frame: 8 weeks
tolerance of treatment: Blood sample: creatinine
tolerance of treatment: Blood sample: creatinine
Time frame: 8 weeks
tolerance of treatment: Blood sample: T4
tolerance of treatment: Blood sample: T4
Time frame: 8 weeks
tolerance of treatment: Blood sample: TSH
tolerance of treatment: Blood sample: TSH
Time frame: 8 weeks
Robert Debré patients: EEG-HR (High Resolution Electroencephalogram)
the criterion used will be the theta-beta ratio.
Time frame: 4 and 8 weeks
Robert Debré patients: qualitative study:
The exploration criterion will be an in-depth description of the experience of the families and the child with regard to treatment with sulforaphane (interest and satisfaction).
Time frame: one month post treatment
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 32 months after the start.
Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 32 months is above that.
Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2026 → Aug 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sulforaphane
Attention Deficit Disorder with Hyperactivity →
Assistance Publique - Hôpitaux de Paris →